Clinical Trial: An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid Tumors

U.S., Aug. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07774611) titled 'An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid Tumors' on Aug. 13.

Brief Summary: This multicenter, open-label Phase Ib/II study with dose escalation and expansion in Chinese patients with advanced solid tumors consists of Part A (SG1827 plus anti-PD-1/PD-L1) and Part B (SG1827 plus anti-PD-1/PD-L1 and bevacizumab), both evaluating safety, tolerability, PK/PD, immunogenicity, and antitumor efficacy.

Study Start Date: Sept. 22

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumors

Intervention: DRUG: SG1827

Intravenous infusion, once every three weeks ...